FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3041400773> ?p ?o ?g. }

• W3041400773 endingPage "534" @default.
• W3041400773 startingPage "519" @default.
• W3041400773 abstract "In intraduodenal administration of /sup 125/I bromelain in the dog, a blood radioactive peak was attained at 4 hr, equivalent to 9.2% of the administered radioactivity, but, over 24 hr after the administration, 0.213 to 0.263% of the dose was found in the high molecular serum fraction, 21% of which was respondible for the absorbed as intact, equivalent to 0.042 to 0.052% of the administered. The gastrointestinal absorption immunologically proved the same. In intragastric administration of enteric-coated capsules containing /sup 125/I-bromelain as much as 1/8 th of the intraduodenal dose, the blood level reached the maximum at 6 hr following a 3 hr lag phase, equivalent to 0.6% of the administered, and 0.013% of the dose was attributed to the radioactivity in the high molecular serum fraction. The presence of bromelain absorbed was not evidenced immunologically. In intravenous administration of /sup 125/I-bromelain, /sup 125/I-bromelain was eliminated from the circulation at 50 min half-life, and low /sup 125/I molecules were detected immediately after the administration; it is indicative of the rapid break-down of /sup 125/I-bromelain by serum proteases. A binding of these low /sup 125/I-molecules to serum proteins was also revealed. A 24 hr urinary collection was found 68% of the dose. As for the anti-inflammatory effect of bromelain on the carrageenin-induced edema in the rat hind paw, bromelain orally administered in enteric-coated form showed 6.6% inhibition of edema at 73.5 mg/kg dose, and 39.0% inhibition at 120 mg/kg dose. This effect highly significant and almost equivalent to that obtained with hydrocortisone given at 10 mg/kg dose, while no powdered bromelain orally administered showed an inhibitory effect on the edema at 20 - 300 mg/kg dose level. The data obtained here indicate that orally administered bromelain is absorbable from the gastrointestinal tract and exhibits fairly potent anti-inflammatory activity on the exudative phases in enteric-coated form." @default.
• W3041400773 created "2020-07-16" @default.
• W3041400773 creator A5000610005 @default.
• W3041400773 creator A5030220384 @default.
• W3041400773 creator A5037174509 @default.
• W3041400773 creator A5085454733 @default.
• W3041400773 date "1972-01-01" @default.
• W3041400773 modified "2023-10-16" @default.
• W3041400773 title "Gastrointestinal Absorption and Anti-Inflammatory Effect of Bromelain" @default.
• W3041400773 cites W1775749144 @default.
• W3041400773 cites W1893651774 @default.
• W3041400773 cites W1981819970 @default.
• W3041400773 cites W1998835544 @default.
• W3041400773 cites W2038890471 @default.
• W3041400773 cites W2052518216 @default.
• W3041400773 cites W2080592645 @default.
• W3041400773 cites W2085682359 @default.
• W3041400773 cites W2333421299 @default.
• W3041400773 cites W2334165365 @default.
• W3041400773 cites W2552920334 @default.
• W3041400773 doi "https://doi.org/10.1016/s0021-5198(19)31648-8" @default.
• W3041400773 hasPublicationYear "1972" @default.
• W3041400773 type Work @default.
• W3041400773 sameAs 3041400773 @default.
• W3041400773 citedByCount "6" @default.
• W3041400773 countsByYear W30414007732014 @default.
• W3041400773 countsByYear W30414007732017 @default.
• W3041400773 countsByYear W30414007732021 @default.
• W3041400773 crossrefType "journal-article" @default.
• W3041400773 hasAuthorship W3041400773A5000610005 @default.
• W3041400773 hasAuthorship W3041400773A5030220384 @default.
• W3041400773 hasAuthorship W3041400773A5037174509 @default.
• W3041400773 hasAuthorship W3041400773A5085454733 @default.
• W3041400773 hasBestOaLocation W30414007731 @default.
• W3041400773 hasConcept C120665830 @default.
• W3041400773 hasConcept C121332964 @default.
• W3041400773 hasConcept C125287762 @default.
• W3041400773 hasConcept C181199279 @default.
• W3041400773 hasConcept C185592680 @default.
• W3041400773 hasConcept C2776714187 @default.
• W3041400773 hasConcept C2777334355 @default.
• W3041400773 hasConcept C55493867 @default.
• W3041400773 hasConcept C71924100 @default.
• W3041400773 hasConcept C98274493 @default.
• W3041400773 hasConceptScore W3041400773C120665830 @default.
• W3041400773 hasConceptScore W3041400773C121332964 @default.
• W3041400773 hasConceptScore W3041400773C125287762 @default.
• W3041400773 hasConceptScore W3041400773C181199279 @default.
• W3041400773 hasConceptScore W3041400773C185592680 @default.
• W3041400773 hasConceptScore W3041400773C2776714187 @default.
• W3041400773 hasConceptScore W3041400773C2777334355 @default.
• W3041400773 hasConceptScore W3041400773C55493867 @default.
• W3041400773 hasConceptScore W3041400773C71924100 @default.
• W3041400773 hasConceptScore W3041400773C98274493 @default.
• W3041400773 hasIssue "4" @default.
• W3041400773 hasLocation W30414007731 @default.
• W3041400773 hasOpenAccess W3041400773 @default.
• W3041400773 hasPrimaryLocation W30414007731 @default.
• W3041400773 hasRelatedWork W118449968 @default.
• W3041400773 hasRelatedWork W2090283026 @default.
• W3041400773 hasRelatedWork W2124348372 @default.
• W3041400773 hasRelatedWork W2404961272 @default.
• W3041400773 hasRelatedWork W2410918544 @default.
• W3041400773 hasRelatedWork W2748952813 @default.
• W3041400773 hasRelatedWork W2755247557 @default.
• W3041400773 hasRelatedWork W2899084033 @default.
• W3041400773 hasRelatedWork W4200239183 @default.
• W3041400773 hasRelatedWork W4309306507 @default.
• W3041400773 hasVolume "22" @default.
• W3041400773 isParatext "false" @default.
• W3041400773 isRetracted "false" @default.
• W3041400773 magId "3041400773" @default.
• W3041400773 workType "article" @default.